Observational study of progressive pulmonary fibrosis (PPF) in China
Part of Lungs & breathing clinical trials.
This study is a registry that collects information from people in China who have progressive pulmonary fibrosis (PPF), a lung condition that gets worse over time. It aims to better understand the disease and help doctors improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with progressive pulmonary fibrosis (PPF) in the last year.
- You must not have idiopathic pulmonary fibrosis (IPF).
- You must have had a high-resolution CT (HRCT) scan of your chest.
- You must be willing to sign a consent form to join the study.
- You cannot be taking part in another medication trial right now (unless that trial is over or you've been off the study drug for at least 2 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called HSK44459 for people with progressive pulmonary fibrosis (PPF). It aims to see if the drug can help slow lung damage and improve breathing. You may join if you are not taking certain other fibrosis drugs or have been on a stable dose for at least 12 weeks.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
This study follows people with COPD (chronic lung disease) over many years to better understand the condition. It may help doctors learn what factors predict worsening over time.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This study keeps a national record of people diagnosed with cystic fibrosis (CF) in China. It aims to better understand CF over time and may help future care by improving how patients are tracked and studied.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.